PPARG and breast carcinoma: In addition to PPAR‐γ, activation of PPAR‐α by its agonist clofibrate has also been shown to downregulate the inflammatory activity of COX‐2 and 5‐LO, and inhibits cell cycle‐related kinases and breast cancer cell survival.37